Since the introduction of insulin almost a century ago, more than 80 peptide drugs have
reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis …

Biocatalysis, using enzymes for organic synthesis, has emerged as powerful tool for the
synthesis of active pharmaceutical ingredients (APIs). The first industrial biocatalytic …

ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers (ARBs)
are equally guideline-recommended first-line treatments for hypertension, yet few head-to …

Importance The association between industry payments to physicians and prescribing rates
of the brand-name medications that are being promoted is controversial. In the United …

(ACCF) guidelines on secondary prevention, 1 important evidence from clinical trials has
emerged that further supports and broadens the merits of intensive risk-reduction therapies …

Background In patients who have vascular disease or high-risk diabetes without heart
failure, angiotensin-converting–enzyme (ACE) inhibitors reduce mortality and morbidity from …

Background Angiotensin receptor blockers (ARB) and angiotensin converting enzyme (ACE)
inhibitors are known to reduce proteinuria. Their combination might be more effective than …

Importance Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor
blockers (ARBs) may have different effects on cardiovascular (CV) events in patients with …

Objective To investigate whether angiotensin receptor blockers protect against Alzheimer's
disease and dementia or reduce the progression of both diseases. Design Prospective …

Angiotensin-converting enzyme (ACE) is a zinc-dependent peptidase responsible for
converting angiotensin I into the vasoconstrictor angiotensin II. However, ACE is a relatively …